Endo International

Endo International plc
Company type	Public
Traded as	Expert Market: ENDPQ; Nasdaq: ENDP;
ISIN	IE00BJ3V9050
Industry	Pharmaceutical
Predecessor	Endo Pharmaceuticals Inc. (before the 2014 tax inversion to Ireland)
Founded	1997
Headquarters	(Legal) Dublin, Ireland; (Operational) Malvern, Pennsylvania, United States;
Key people	Paul Campanelli (CEO); Blaise Coleman (CFO);
Products	Adrenalin; Percocet; Supprelin LA; Testopel; Vasostrict; Xiaflex;
Revenue	US$2,993 million (2021); US$2,903 million (2020);
Operating income	US$−547 million (2021); US$−27 million (2020);
Net income	US$−613 million (2021); US$184 million (2020);
Total assets	US$2,715 million (2021); US$2,413 million (2020);
Number of employees	3103 (2021)
Website	endo.com
	Footnotes / references; Financials

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.